← All trials
NCT05044871
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jan 1, 2022
- Primary completion
- Jun 1, 2024
- Completion date
- Dec 1, 2027
- First posted
- Sep 16, 2021
- Last posted
- Oct 14, 2021
- Enrollment
- 160
- Arms / groups
- 5 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Huazhong University of Science and TechnologyLead sponsor
- Jiangnan UniversityCollaborator
- Shandong UniversityCollaborator
- Sun Yat-Sen UniversityCollaborator
- Chinese Academy of Medical SciencesCollaborator
- Central South UniversityCollaborator
- Huazhong University of Science and TechnologyReponsible party - principal investigator
- Huazhong University of Science and TechnologyOverall official - principal investigator
- Sun Yat-Sen UniversityCollaborator
- Jilin Provincial Tumor HospitalCollaborator
- Wuhan UniversityCollaborator
- Anhui Medical UniversityCollaborator
- Zhejiang UniversityCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.